We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current EVTA market cap is 1.54B. The company's latest EPS is EUR -0.2371 and P/E is -41.54.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 446.44M | 500.92M | 618.03M | 751.45M | 781.43M |
| Operating Income | 60.38M | 38.09M | 24.43M | 4.89M | -68.26M |
| Net Income | 38.07M | 6.25M | 215.51M | -175.66M | -83.91M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 1.18B | 1.46B | 2.24B | 2.26B | 2.25B |
| Total Liabilities | 703.88M | 740.05M | 857.48M | 1.07B | 1.13B |
| Total Equity | 477.03M | 722.85M | 1.38B | 1.19B | 1.12B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 42.22M | 44.72M | 122.24M | 203.11M | 36.44M |
| Investing | -86.63M | -155.09M | -243.86M | -415.82M | -13.29M |
| Financing | 211.26M | 246.41M | 398.43M | -52.41M | 71.96M |
| Market Cap | 1.54B |
| Price to Earnings Ratio | -41.54 |
| Price to Sales Ratio | 4.46 |
| Price to Cash Ratio | 6.82 |
| Price to Book Ratio | 3.11 |
| Dividend Yield | - |
| Shares Outstanding | 353.91M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.22 (4.95%) |
| Company Name | Evotec SE |
| Address |
essener bogen 7 hamburg 22419 |
| Website | https://www.evotec.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
